261 related articles for article (PubMed ID: 18829493)
21. A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability.
Patel N; Sun L; Moshinsky D; Chen H; Leahy KM; Le P; Moss KG; Wang X; Rice A; Tam D; Laird AD; Yu X; Zhang Q; Tang C; McMahon G; Howlett A
J Pharmacol Exp Ther; 2003 Sep; 306(3):838-45. PubMed ID: 12766257
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors.
Borzilleri RM; Zheng X; Qian L; Ellis C; Cai ZW; Wautlet BS; Mortillo S; Jeyaseelan R; Kukral DW; Fura A; Kamath A; Vyas V; Tokarski JS; Barrish JC; Hunt JT; Lombardo LJ; Fargnoli J; Bhide RS
J Med Chem; 2005 Jun; 48(12):3991-4008. PubMed ID: 15943473
[TBL] [Abstract][Full Text] [Related]
23. [Autocrine stimulation of receptor-tyrosine kinases (RTK) in human tumor cell lines in vitro: therapeutic implications].
Gaumann A; Groot M; Drexler HC; Breier G
Verh Dtsch Ges Pathol; 2003; 87():232-9. PubMed ID: 16888917
[TBL] [Abstract][Full Text] [Related]
24. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response.
Griffin RJ; Williams BW; Wild R; Cherrington JM; Park H; Song CW
Cancer Res; 2002 Mar; 62(6):1702-6. PubMed ID: 11912143
[TBL] [Abstract][Full Text] [Related]
25. Ectopic activity of fibroblast growth factor receptor 1 in hepatocytes accelerates hepatocarcinogenesis by driving proliferation and vascular endothelial growth factor-induced angiogenesis.
Huang X; Yu C; Jin C; Kobayashi M; Bowles CA; Wang F; McKeehan WL
Cancer Res; 2006 Feb; 66(3):1481-90. PubMed ID: 16452204
[TBL] [Abstract][Full Text] [Related]
26. Deregulation of Flk-1/vascular endothelial growth factor receptor-2 in fibroblast growth factor receptor-1-deficient vascular stem cell development.
Magnusson P; Rolny C; Jakobsson L; Wikner C; Wu Y; Hicklin DJ; Claesson-Welsh L
J Cell Sci; 2004 Mar; 117(Pt 8):1513-23. PubMed ID: 15020678
[TBL] [Abstract][Full Text] [Related]
27. Antisense to cyclin D1 inhibits vascular endothelial growth factor-stimulated growth of vascular endothelial cells: implication of tumor vascularization.
Yasui M; Yamamoto H; Ngan CY; Damdinsuren B; Sugita Y; Fukunaga H; Gu J; Maeda M; Takemasa I; Ikeda M; Fujio Y; Sekimoto M; Matsuura N; Weinstein IB; Monden M
Clin Cancer Res; 2006 Aug; 12(15):4720-9. PubMed ID: 16899623
[TBL] [Abstract][Full Text] [Related]
28. Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition.
Zips D; Eicheler W; Geyer P; Hessel F; Dörfler A; Thames HD; Haberey M; Baumann M
Cancer Res; 2005 Jun; 65(12):5374-9. PubMed ID: 15958586
[TBL] [Abstract][Full Text] [Related]
29. PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy.
Hess-Stumpp H; Haberey M; Thierauch KH
Chembiochem; 2005 Mar; 6(3):550-7. PubMed ID: 15742376
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of fibroblast growth factor receptor signaling attenuates atherosclerosis in apolipoprotein E-deficient mice.
Raj T; Kanellakis P; Pomilio G; Jennings G; Bobik A; Agrotis A
Arterioscler Thromb Vasc Biol; 2006 Aug; 26(8):1845-51. PubMed ID: 16709940
[TBL] [Abstract][Full Text] [Related]
31. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma.
Pang R; Poon RT
Cancer Lett; 2006 Oct; 242(2):151-67. PubMed ID: 16564617
[TBL] [Abstract][Full Text] [Related]
32. Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice.
Ng SS; MacPherson GR; Gütschow M; Eger K; Figg WD
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4192-7. PubMed ID: 15217957
[TBL] [Abstract][Full Text] [Related]
33. [Inhibitory effects of ampelopsin on angiogenesis].
Luo GQ; Zeng S; Liu DY
Zhong Yao Cai; 2006 Feb; 29(2):146-50. PubMed ID: 16617784
[TBL] [Abstract][Full Text] [Related]
34. Xenografts of human hepatocellular carcinoma: a useful model for testing drugs.
Huynh H; Soo KC; Chow PK; Panasci L; Tran E
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4306-14. PubMed ID: 16857806
[TBL] [Abstract][Full Text] [Related]
35. Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition.
Allen E; Walters IB; Hanahan D
Clin Cancer Res; 2011 Aug; 17(16):5299-310. PubMed ID: 21622725
[TBL] [Abstract][Full Text] [Related]
36. Blockade of vascular endothelial growth factor receptor signal pathway and antitumor activity of ON-III (2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone), a component from Chinese herbal medicine.
Zhu XF; Xie BF; Zhou JM; Feng GK; Liu ZC; Wei XY; Zhang FX; Liu MF; Zeng YX
Mol Pharmacol; 2005 May; 67(5):1444-50. PubMed ID: 15703376
[TBL] [Abstract][Full Text] [Related]
37. Potential involvement of the cyclooxygenase-2 pathway in hepatocellular carcinoma-associated angiogenesis.
Zhao QT; Yue SQ; Cui Z; Wang Q; Cui X; Zhai HH; Zhang LH; Dou KF
Life Sci; 2007 Jan; 80(5):484-92. PubMed ID: 17097688
[TBL] [Abstract][Full Text] [Related]
38. Expressions of basic fibroblast growth factor and its receptors and their relationship to proliferation of human hepatocellular carcinoma cell lines.
Ogasawara S; Yano H; Iemura A; Hisaka T; Kojiro M
Hepatology; 1996 Jul; 24(1):198-205. PubMed ID: 8707262
[TBL] [Abstract][Full Text] [Related]
39. A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer.
Nakamura K; Yashiro M; Matsuoka T; Tendo M; Shimizu T; Miwa A; Hirakawa K
Gastroenterology; 2006 Nov; 131(5):1530-41. PubMed ID: 17101326
[TBL] [Abstract][Full Text] [Related]
40. AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma.
Sathornsumetee S; Hjelmeland AB; Keir ST; McLendon RE; Batt D; Ramsey T; Yusuff N; Rasheed BK; Kieran MW; Laforme A; Bigner DD; Friedman HS; Rich JN
Cancer Res; 2006 Sep; 66(17):8722-30. PubMed ID: 16951188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
